Study of a new drug for cancer-related weight loss
Part of Cancer clinical trials.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have cancer-related weight loss and muscle wasting (cachexia) confirmed by your doctor.
- You must be able to get around and take care of yourself (ECOG status 0 or 1).
- You cannot be on tube feedings or IV nutrition for the past month.
- Your weight loss must not be caused by another illness or a feeding problem.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational injection called INB301 to see if it can help reduce weight loss and improve appetite in people with cancer-related wasting (cachexia). It is a phase 1/2 study, so it is one of the first times the drug is given to people, and safety is a key goal.
This study tests a new drug called GFS202A for people with advanced solid tumors who are experiencing weight loss or have a low body mass index (cachexia). The goal is to see if the drug is safe and can help improve appetite and weight.
This trial tests a new drug called JMT203 for people with cancer-related weight loss (cachexia). It aims to see if the drug can help prevent or reverse weight loss in patients with certain solid tumors who are also receiving or have recently completed anti-cancer therapy.
This study tests a new drug called DS010 to see if it can help people with cancer-related weight loss and muscle loss (cachexia). The goal is to improve appetite and strength, which may help you feel better during cancer treatment.
This study tests whether MitoQ, a dietary supplement that helps cells produce energy, can improve weight loss and appetite in people with cancer. It may also help slow down the muscle loss that often comes with cancer, so you can feel stronger and have a better quality of life.
This trial tests a new drug, ASCA101, for people with certain cancers who are experiencing unwanted weight loss (cachexia). It aims to see if the drug can help improve appetite and stabilize weight. Participants must have colorectal, ovarian, or lung cancer and meet specific weight loss criteria.
Hear when a new Cancer Cachexia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.